Insuffisances cardiaques d’origine médicamenteuse (en dehors des anthracyclines)

作者: Christian Libersa , Sophie Gautier , Nabil Ait Said , Laurent Ferez , Jacques Caron

DOI: 10.2515/THERAPIE:2004024

关键词:

摘要: A partir d'une revue de la litterature et des observations base donnees nationale francaise pharmacovigilance pour periode 1984 a avril 2003, sont presentes les principaux medicaments responsables ou revelateurs insuffisance cardiaque. Plusieurs grandes classes pharmacologiques se distinguent : outre certains antimitotiques dont anthracyclines, nombreux tels que immunomodulateurs, anti-inflammatoires (y compris coxibs), antiarythmiques, anesthesiques, antipsychotiques, antidiabetiques (dont glitazones) impliques dans survenue decompensations cardiaques. Il est habituel classer en trois categories (i) susceptibles provoquer insuffisances cardiaques novo (tels cyclophosphamide, paclitaxel, mitoxantrone, interferons, interleukine-2...) ; (ii) d'aggraver une cardiaque preexistante β-bloquants, antagonistes du calcium, non steroidiens steroidiens, sympathomimetiques...); (iii) provoquant exceptionnellement Cette montre cette classification fait artificielle si preoccupation toxicite doit etre constante lors maniement anticancereux il convient d'etre attentif au chez le sujet insuffisant cardiaque, y lorsque situation clinique bien equilibree, tenant compte, particulier, terrain interactions medicamenteuses potentielles.

参考文章(151)
Henner Wd, Antman K, Peters Wp, Eder Jp, Schnipper L, Frei E rd, Pharmacokinetics and immediate effects of high-dose carmustine in man. Cancer treatment reports. ,vol. 70, pp. 877- 880 ,(1986)
Spier Sa, Frontera Ma, Unexpected deaths in depressed medical inpatients treated with fluoxetine. The Journal of Clinical Psychiatry. ,vol. 52, pp. 377- ,(1991)
Vinita B. Pai, Milap C. Nahata, Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Safety. ,vol. 22, pp. 263- 302 ,(2000) , 10.2165/00002018-200022040-00002
MA Goldberg, JH Antin, EC Guinan, JM Rappeport, Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood. ,vol. 68, pp. 1114- 1118 ,(1986) , 10.1182/BLOOD.V68.5.1114.1114
B Desvergne, B Staels, J Auwerx, T Lemberger, W Wahli, R Saladin, Regulation of the peroxisome proliferator-activated receptor alpha gene by glucocorticoids Journal of Biological Chemistry. ,vol. 269, pp. 24527- 24530 ,(1994) , 10.1016/S0021-9258(17)31420-5
Bernadine H. Bulkley, William C. Roberts, Steroid therapy during acute myocardial infarction The American Journal of Medicine. ,vol. 56, pp. 244- 250 ,(1974) , 10.1016/0002-9343(74)90603-2
J. B. Rockoff, J. G. Dobson, Inhibition by adenosine of catecholamine-induced increase in rat atrial contractility American Journal of Physiology-heart and Circulatory Physiology. ,vol. 239, ,(1980) , 10.1152/AJPHEART.1980.239.3.H365
J. Verweij, G. J. J. Teule, A. J. Funke-Küpper, H. M. Pinedo, A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C. Medical oncology and tumor pharmacotherapy. ,vol. 5, pp. 159- 163 ,(1988) , 10.1007/BF02986439